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ABSTRACT
Objective: To identify publication and citation trends,
most productive institutions and countries, top
journals, most cited articles and authorship networks
from articles that used and analysed data from
primary care databases (CPRD, THIN, QResearch)
of pseudonymised electronic health records
(EHRs) in UK.
Methods: Descriptive statistics and scientometric
tools were used to analyse a SCOPUS data set of 1891
articles. Open access software was used to extract
networks from the data set (Table2Net), visualise and
analyse coauthorship networks of scholars and
countries (Gephi) and density maps (VOSviewer) of
research topics co-occurrence and journal cocitation.
Results: Research output increased overall at a yearly
rate of 18.65%. While medicine is the main field of
research, studies in more specialised areas include
biochemistry and pharmacology. Researchers from UK,
USA and Spanish institutions have published the most
papers. Most of the journals that publish this type of
research and most cited papers come from UK and
USA. Authorship varied between 3 and 6 authors.
Keyword analyses show that smoking, diabetes,
cardiovascular diseases and mental illnesses, as well
as medication that can treat such medical conditions,
such as non-steroid anti-inflammatory agents, insulin
and antidepressants constitute the main topics of
research. Coauthorship network analyses show that
lead scientists, directors or founders of these
databases are, to various degrees, at the centre of
clusters in this scientific community.
Conclusions: There is a considerable increase of
publications in primary care research from EHRs. The
UK has been well placed at the centre of an expanding
global scientific community, facilitating international
collaborations and bringing together international
expertise in medicine, biochemical and pharmaceutical
research.
INTRODUCTION
Big data (analytics) refer to the aggrega-
tion and interrogation of—high volume,
high velocity, high variety—data sets so as to
reveal new, non-obvious, information and
patterns.1 This ﬁeld is advancing because of
technological and scientiﬁc developments in
information infrastructure and digitisation.2
For governments, opening up the data sets
states hold about their citizens is believed to
have, through computational and algorith-
mic analyses, a disruptive and transformative
effect on knowledge.3 In the UK, big (open)
data have been at the forefront of research
activity and policymaking. Termed as one of
the eight great technologies,4 UK has
embraced the big (open) data movement
more than many other developed countries
(eg, USA, Australia, France).3 One area of
particular relevance to big data analytics is
healthcare.
In UK, the National Health Service (NHS)
is organised around primary care and, unless
there is an accident or emergency, whenever
citizens would like to use the NHS they have
to go through their primary care physician,
known in the UK as a general practitioner
(GP). From there, they can be referred to a
specialist at a hospital if necessary. Secondary
care clinicians can then feedback informa-
tion to GPs. Since the vast majority of the
population (98%) is registered with a
general practice, GPs act not only as the
main gatekeepers for the NHS but also as
important custodians of a longitudinal elec-
tronic health record (EHR).5 There are now
many ongoing primary care databases of
Strengths and limitations of this study
▪ First study to perform a scientometric analysis of
research output from primary care databases of
electronic patient records.
▪ We analysed articles published from 1995 to
2015 in order to explore the historical breadth
and growth of this type of research.
▪ The analysis is limited to articles and structured
data retrieved from the Scopus database.
▪ Some latest articles and related citations might
not have appeared in Scopus when the data set
was extracted.
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anonymised patient records in UK that can be used for
healthcare research. These population-based databases
contain data originating from routine general practice.
Some newly established databases and research plat-
forms of linked EHRs include ResearchOne6 and
CALIBER.7 While there are more than 9600 general
practices in UK that could potentially contribute data to
these databases,8 it is usually 6–10% of these practices
that do so.
Such databases are usually used for cross-sectional
surveys, case–control or cohort studies and for epidemio-
logical, drug safety, clinical and healthcare usage
research purposes. They rely heavily on individual
general practices voluntarily contributing data via the
propriety clinical systems they use to maintain these
patient records. The records are usually anonymised or
pseudoanonymised at source by allocating a unique
number to each patient to allow for the updates of the
records as well as for their linkage to other data sets,
such as national mortality, national cancer registration
and hospital records as well as with socioeconomic, eth-
nicity and environmental data sets. Access to these data
sets is usually granted after scientiﬁc and ethics review
and can be tailored to customer requirements. In this
study, we examined the research output of three such
databases that are well established in the research com-
munity and have contributed to a substantial number of
scientiﬁc studies and publications. These are the Clinical
Practice Research Datalink (CPRD),9 The Health
Improvement Network (THIN)10 and QResearch.11
The CPRD (formerly known as the General Practice
Research Database) is a not-for-proﬁt research service
funded by the NHS National Institute for Health
Research (NIHR) and the Medicines and Healthcare
products Regulatory Agency (MHRA). It is owned by the
UK Department of Health and contains the records of
11 million patients (4.4 million active) from 674 general
practices.5 There is a service cost associated with the
preparation of the requested data. Unlike the other ser-
vices described below, CPRD does not extract data from
a particular propriety clinical system. Any general prac-
tice can contribute data after a data sharing agreement
with the software supplier. Importantly, it is the only
database accessible online.12 The THIN database con-
tains the health records of 12 million patients from
around 600 general practices that use the Vision clinical
system by In Practice Systems (INPS). IMS Health can
provide access to data, for example, via a yearly subli-
cense to an academic institution. THIN is the only data-
base that can provide access to data for for-proﬁt
companies. QResearch is a research service located at
the University of Nottingham. Its database contains the
health records of 18 million patients from 1000 general
practices that use the EMIS clinical system. Only aca-
demics employed by a UK university can have (in site)
access only to a sample of the data set (maximum
100 000 patients) that is sufﬁcient to answer a speciﬁc
research question or hypothesis. As this research service
is not-for-proﬁt and entirely self-funded, there is usually
a fee to be paid to cover the cost of the data extraction.
The strengths of these databases lie in their size,
breadth, representativeness of the UK population, long-
term follow-up and data quality.5 They include good
information on morbidity and lifestyle, prescribing, pre-
ventive care, current standards of care and interpractice
variation.13 Since they are continually (and automatic-
ally) updated, they are ideal for researchers to discover
and monitor healthcare trends as well as the effectiveness
of new interventions and treatments, with minimum cost.
They are increasingly linked to secondary care and mor-
tality data sets. In contrast, their weaknesses include the
fact that data are extracted from propriety clinical systems
developed for patient management and not for health-
care research. There are issues of missing data (eg, from
healthy patients), variable deﬁnitions for diagnoses and
incomplete secondary care data (eg, hospital admis-
sions). Wider health data (eg, treatment adherence, over
the counter medication) and data about subpopulations
(eg, prisoners, homeless people, refugees, travellers) are
not captured adequately.5 Information governance and
informed consent procedures around the data sharing of
EHRs for research are still considered complex.14 These
databases also require considerable clinical and scientiﬁc
expertise, as well as technical capacity in data management
to support research. When selecting a particular data
resource for an observational study, researchers have to
consider several other factors, such as the population
covered and its geographical distribution, data capture
and latency, linkage with other resources, privacy and
security, quality and validation.15
Nonetheless, these databases are highly regarded
within the research community since they have proved
their value in helping researchers reach deﬁnitive
answers in various healthcare debates of considerable
public interest, particularly where other types of research
have produced contradictory evidence. For example, in
2004 researchers from UK and Canada proved beyond
doubt that measles–mumps–rubella (MMR) vaccination is
not associated with autism in children.16 In contrast to
expensive, time-consuming, and unrepresentative (of the
population) traditional randomised trials,17 large-scale
and randomised observational (comparative) evaluations
of treatments and medications are minimally obtrusive
for clinicians and patients and can support faster turn-
around times for pragmatic evidence useful in clinical
practice.18
The aim of this study was to perform a scientometric
analysis of articles, published from 1995 to 2015, which
have used data from at least one of these primary care
databases. This empirical, semiautomated, method of
quantitatively analysing a large number of publications
provides a reliable and objective examination of the
current status and trends as well as the structure and
dynamics of this scientiﬁc ﬁeld.19 20 In this way, policy-
makers, research funding bodies but most importantly
new researchers entering this ﬁeld can have a general
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overview of its knowledge base and an indication of what
kind of network features, research activities and topics of
interest are driving it.20 21 To the best of our knowledge,
this is the ﬁrst study of a systematic mapping of primary
care databases research output.
METHODS
In this study, Elsevier’s Scopus database (http://www.
scopus.com) was selected as the source of structured
data on articles. This database covers more scientiﬁc arti-
cles than other databases (eg, Thomson Reuters Web of
Science) and has the advantage of providing advance
export functionality of structured data, including full cit-
ation information, abstracts, keywords and references.
On 30 October 2015, we searched, using the document
search functionality, for all articles containing the terms
‘General Practice Research Database (GPRD)’ OR
‘Clinical Practice Research Datalink (CPRD)’ OR ‘The
Health Improvement Network (THIN)’ OR ‘QResearch’
in article title, abstract and keywords.
The results were then limited to articles, articles in press,
conference papers, reviews, book chapters and short surveys.
Notes, letters, editorials and errata were excluded from the
analysis. From there, we compared the resulted records
with the bibliographic lists maintained by these data-
bases22–24 so as to include articles that could not be
retrieved using the above search queries. Data cleansing
included the removal of duplicate records and records
that were missing essential information for the analysis
(eg, article title, journal). The ﬁelds of authors, year,
source title, afﬁliations, author keywords and document type
were used for the analysis.
The ﬁnal bibliography retrieved from Scopus was
imported to Table 2 Net25 to extract networks of authors
and contributing countries. It was then imported to
Gephi26 where the ForceAtlas 2 algorithm27 was used to
visualise the structural proximities for the communities
of authors and contributing countries. The VOSviewer
(V.1.6.3)28 software was used to visualise bibliometric net-
works and densities29 of frequent terms and journals. All
other statistical analyses were performed using Microsoft
Excel. We used the Journal Citation Reports ( JCR)
Science Edition 2014 to extract impact factor values for
the identiﬁed journal titles.
RESULTS
A total of 1891 papers from 1995 to 2015 were included
in this bibliometric and scientometric analysis. The
results are presented below.
Publication and citation trends
The literature related to the 3 primary care databases in
England increased gradually from 7 papers in 1995 to
171 in 2015 (table 1). We estimated their compound
annual growth rate (CAGR), for the years 1995–2014, to
be 18.65%. The vast majority of papers were published
in English across 425 different sources (16.76% CAGR
for 1995–2014). In total, these papers have already been
cited 73 929 times. There is, however, a small percentage
of 1.16% (n=163) papers that have not yet been cited
yet. The average citation per year is ∼3.52.
We explored the distribution of publications by docu-
ment type. This is presented in table 2 to identify the pre-
ferences of scholars using these databases in their
research to share knowledge. The vast majority of scholars
prefer to publish the ﬁndings of their research through
journals, particularly as original articles (96.5%).
Next, we analysed the distribution of papers based on
the academic discipline in which they have been cate-
gorised by Scopus (table 3) and by which each paper
may be attributed to more than one subject area.30
Since we analysed bibliographic data based on published
research using primary care databases, it comes as no
surprise that the vast majority of papers are under the
medicine category. There is, however, a considerable
number of papers (∼25%) under the categories biochem-
istry, genetics and molecular biology and pharmacology,
Table 2 Distribution of scientific literature by document
type
Type No. of papers Per cent
Article 1825 96.5
Conference paper 18 0.95
Book chapter 4 0.21
Review 41 2.16
Short survey 3 0.15
Table 1 Distribution of scientific literature by year
Year
No. of
papers
Per
cent
No. of
citations
No. of different
sources
2015 171 9.04 255 107
2014 214 11.31 1188 114
2013 203 10.73 1934 123
2012 175 9.25 3050 99
2011 148 7.82 3900 100
2010 129 6.82 5232 81
2009 126 6.66 5341 79
2008 115 6.08 4757 73
2007 96 5.07 5232 65
2006 74 3.91 5943 56
2005 81 4.28 5839 56
2004 73 3.86 6411 49
2003 46 2.43 2998 37
2002 52 2.74 3832 37
2001 51 2.69 3770 38
2000 51 2.69 6334 35
1999 26 1.37 1594 21
1998 29 1.53 2582 20
1997 17 0.89 1560 13
1996 7 0.37 1137 7
1995 7 0.37 1040 6
Total 1891 100 73 929 425
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toxicology and pharmaceutics, which indicates an emphasis
on the use of these databases for the study of medica-
tions. It also indicates the potential interest in these
databases from the pharmaceutical sector.
Most productive institutions and countries
For a deeper insight into contribution patterns and sci-
entiﬁc impact, we ﬁrst identiﬁed the top 10 institutions
(by number of papers) authors have used as afﬁliation
and then we analysed citation patterns (table 4). We also
analysed authors’ afﬁliations based on the country of
their institution. For this, each publication was assigned
to its authors’ respective afﬁliated countries so as to
identify the network of multinational collaborations.
The distribution of the top 10 contributing countries is
presented in table 5. Finally, we visualised the network of
contributing countries using Gephi. We ended up with a
network of 29 nodes and 175 edges (ﬁgure 1). Each
node represents a country, while its size denotes the
country’s degree and the colour the number of papers.
The thickness of interconnected lines (edges) denotes
the number of coauthored papers between the
countries.
The majority of the most productive institutions are
universities. Top universities include the University of
Nottingham, Boston University, University College
London (UCL), the London School of Hygiene &
Tropical Medicine and the University of Utrecht. Apart
from these academic institutions, a research unit in
Spain (CEIFE) and the MHRA in the UK are involved in
primary care databases-based research. In this table, we
also report the medians along with the IQRs. From this,
it seems that scholars from CEIFE, University of
Pennsylvania and Boston University are coauthors in
publications that are highly cited compared to the other
institutions in this list. Switzerland, Canada, Sweden,
Germany, France and Italy had no institution among the
top 10 list, although they were ranked among the top 10
productive countries. Most papers are published by scho-
lars from UK (63.56%), followed by the USA and Spain.
With the exception of USA and Canada, most of the
productive countries are in Europe. What is particularly
interesting in these two tables is that scholars in institu-
tions from the USA and Spain produce not only a great
Table 3 Distribution of scientific literature by discipline
Subject
No. of
papers
Per
cent
Medicine 1838 97.2
Biochemistry, genetics and
molecular biology
266 14.1
Pharmacology, toxicology and
pharmaceutics
197 10.4
Neuroscience 78 4.1
Immunology and microbiology 70 3.7
Agricultural and biological
sciences
53 2.8
Nursing 44 2.3
Psychology 21 1.1
Arts and humanities 13 0.7
Environmental science 10 0.5
Table 4 Most productive institutions
Rank Institution
No. of
papers
Per
cent
Total
citations Median (IQR) Country
1 University of Nottingham 266 14.06 11 540 18 (6–44.75) UK
2 Boston University 228 12.05 12 328 21.5 (6–57) USA
3 Centro Espanol de Investigacion
Farmacoepidemiologica (CEIFE)
163 8.62 8493 26 (7–59.5) Spain
4 University College London 156 8.25 5226 14 (4.75–37) UK
5 London School of Hygiene & Tropical
Medicine
124 6.55 3696 14 (4–40.5) UK
6 University of Utrecht 118 6.24 5067 17.5 (4–48.75) The
Netherlands
7 University of Pennsylvania 110 5.81 7508 24.5 (10–64.25) USA
8 Medicines and Healthcare Products
Regulatory Agency
94 4.97 2623 14 (4–33.25) UK
9 King’s College London 92 4.86 2221 13 (4–32.75) UK
10 University of Oxford 86 4.54 1806 9.5 (3–23.25) UK
Table 5 Top contributing countries
Rank Country No. of papers Per cent
1 UK 1202 63.56
2 USA 563 29.77
3 Spain 192 10.15
4 Netherlands 164 8.67
5 Switzerland 115 6.08
6 Canada 112 5.92
7 Sweden 106 5.60
8 Germany 64 3.38
9 France 51 2.69
10 Italy 36 1.90
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number of publications but also publications that are
widely recognised by this scientiﬁc community in terms
of citations.
Taking into account the measurements of weighted
degree, clustering, eigenvector centrality and betweenness
centrality (table 6), we observe that once again the UK,
followed by USA, is placed at the centre of this
scientiﬁc community. With the highest degrees of all
measurements, institutions from this country are the
most well-connected and authoritative ones, facilitating
the linking between institutions in other countries.
Top journals
In table 7, we identify the top 10 journals where most
research is published. Six of these journals are published
by a UK publisher, and the rest are published in the USA.
The journal Pharmacoepidemiology and Drug Safety features
at the top of list, followed by the British Journal of Clinical
Pharmacology and Pharmacotherapy, which signiﬁes the
focus of research, produced from these primary care
databases, on the safe use of medication. This focus can
also be seen in table 3, where (apart from medicine)
most papers are published in the ﬁelds of biochemistry, gen-
etics and molecular biology and pharmacology, toxicology and
pharmaceutics (Scopus classiﬁcation), but also in table 5,
where most of the top-cited papers refer to potential risk
for particular complications/conditions from the use of
speciﬁc medication. More specialised journals, such as
Diabetes Care and Annals of the Rheumatic Diseases, are also
featured in this list, indicating a particular focus of
research activity in speciﬁc spectrums of diseases.
Four journals in this list are open access (BMJ, British
Journal of General Practice, PLoS One, BMJ Open), which
greatly facilitates the sharing of knowledge without lim-
itations. The BMJ enjoys widespread recognition of the
high quality of its published studies, as indicated by the
high impact factor. The rest are behind a pay wall but
offer authors an open access option to publish their
research (hybrid access). An extra column with the
Impact Factors of these top 10 journals from the 2014
JCR was also added in the table.
What is also of particular importance in terms of sci-
entiﬁc impact is that the 10 most cited papers identiﬁed
(see table 8) have not been published in journals in this
Figure 1 Network of contributing
countries.
Table 6 Top countries by centrality
Rank Country Occurrences
Weighted
degree
Page
rank
Eigen
centrality
Closeness
centrality
Betweenness
centrality
1 UK 5770 27.0 0.062 1.0 0.933 0.250
2 USA 2506 26.0 0.060 0.98 0.903 0.229
3 Netherlands 666 22.0 0.047 0.95 0.8 0.049
4 Canada 567 18.0 0.039 0.83 0.717 0.024
5 Switzerland 409 18.0 0.039 0.85 0.717 0.015
6 Italy 85 17.0 0.037 0.78 0.7 0.024
7 Spain 481 17.0 0.037 0.82 0.7 0.011
8 Australia 37 16.0 0.036 0.76 0.682 0.024
9 Sweden 315 16.0 0.036 0.77 0.682 0.023
10 Germany 121 16.0 0.036 0.71 0.682 0.020
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list. However, by performing a (full counting) analysis of
cocitation links in VOSviewer (ﬁgure 2) for journals
cited in the Scopus data set (minimum number of cita-
tions=10) we see that most of this list is represented here
(blue—lowest density, red—highest density).
Most cited papers
Next, we focused on the top 10 papers31–40 and cal-
culated the total count of citations for each paper
(table 8) for the period 1995–2015. Citations totalled
7194 (1.02%) of all citations in this data set. It seems
that these studies in dementia, psoriasis, fractures, car-
diovascular diseases and gastrointestinal complications
in relation to certain medications have been of great
interest in this scientiﬁc community. The majority of the
top 10 most cited papers (60%) are open access at the
publisher’s website and can be freely read by anyone.
Of the 10 papers, 8 are single country papers, while
none were singled authored. Again, the USA has a con-
siderable presence in this list, producing papers that are
highly cited. In addition, many of the highly productive
authors identiﬁed (table 10) were also found in this list.
Authorship patterns and networks
Authorship distributions varied from single to a
maximum of 155 authors—for a study about the feasibil-
ity of international collaboration to evaluate, based on a
common protocol, the risk of Guillain–Barré syndrome
following pH1N1 vaccination.41 In total, there were 9385
authors involved in the 1981 papers during 1995–2015.
In table 9, we can see that more than three-quarters of
all papers were published by three or more authors.
Only 1% of papers were written by a single author, while
ﬁve papers did not have any authorship details. Almost a
quarter of all papers was published by four authors,
which have been widely cited across this scientiﬁc com-
munity. This indicates the high degree of expert
collaboration in this ﬁeld, that is necessary in analysing
millions of primary care records.
Table 10 provides the ranking of the top 10 scholars,
ﬁrst, in terms of research productivity based on the
overall number of coauthored papers. While, generally,
most scholars are from the UK, the Director of the
Spanish Centre for Pharmacoepidemiologic Research
(CEIFE)42 is the scholar with the most published
research from these primary care databases. Also, there
are researchers in this ﬁeld who do not necessarily come
from the academic environment. The pharmaceutical
sector is actively involved in knowledge production from
electronic primary care records.
Considering only those scholars who have coauthored
at least two papers in this data set, the analysis suggested
a network (ﬁgure 3) with 1261 nodes and 6186 edges.
Here, each node represents an author, while its size
denotes the number of author’s papers. The intercon-
nected lines (edges) denote the coauthored papers
between those authors. For better visualisation, we limited
the number of minimum degrees to 5 (maximum
degrees=145). After a modularity measurement, to iden-
tify community structure,43 we observe some established
collaborative teams (clusters with different colours)
around speciﬁc and highly productive scholars in the ana-
lysis of data from primary care databases also found in
table 10. We also observe a new (blue) cluster around the
lead statistician for THIN44—one of the three primary
care databases studied.
Taking into account the measurements of weighted
degree, clustering, eigenvector centrality and betweenness central-
ity (table 10), results indicate a cluster placed at the
centre of this scientiﬁc community. With the lowest
degree of clustering and the highest degrees of all the
other measurements, its prominent scholar is the most
well-connected, facilitating, more than any other scholar,
linking between other scientiﬁc clusters and scholars.
Table 7 Top journals of published research
Rank Journal name
No. of
papers
Per
cent Publisher
Impact
factor
Open
access Country
1 Pharmacoepidemiology and
Drug Safety
115 6.08 Wiley 2.939 Hybrid UK
2 British Medical Journal 100 5.28 BMJ Publishing Group 17.445 Full UK
3 British Journal of General
Practice
67 3.54 Royal College of
General Practitioners
2.294 Full UK
4 British Journal of Clinical
Pharmacology
57 3.01 Wiley 3.878 Hybrid UK
5 PLoS One 51 2.69 Public Library of Science 3.234 Full USA
6 BMJ Open 41 2.16 BMJ Publishing Group 2.271 Full UK
7 Pharmacotherapy 34 1.79 Wiley 2.662 Hybrid USA
8 Diabetes Care 30 1.58 American Diabetes
Association
8.420 Hybrid USA
9 Epidemiology 24 1.26 Wolters Kluwer 6.196 Hybrid USA
10 Annals of the Rheumatic
Diseases
23 1.21 BMJ Publishing Group 10.377 Hybrid UK
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Table 8 Most cited papers
Rank Authors/title Year Country Journal
Impact
factor Citations
Open
access
1 Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA 2000 USA Lancet 45.217 1322 No
Statins and the risk of dementia
2 Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel
AB
2006 USA Journal of the American
Medical Association
35.289 854 Yes
Risk of myocardial infarction in patients with psoriasis
3 Van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C 2000 UK Journal of Bone and
Mineral Research
6.832 796 Yes
Use of oral corticosteroids and risk of fractures
4 Henry D, Lim LLY, Rodriguez LAG, Perez Gutthann S, Carson JL,
Griffin M, Savage R Logan R, Moride Y, Hawkey C, Hill S, Fries JT
1996 Australia, Spain,
USA, New Zealand,
UK
British Medical Journal 17.445 688 Yes
Variability in risk of gastrointestinal complications with individual
non-steroidal anti-inflammatory drugs: Results of a collaborative
meta-analysis
5 Yang YX, Lewis JD, Epstein S, Metz DC 2006 USA Journal of the American
Medical Association
35.289 637 Yes
Long-term proton pump inhibitor therapy and risk of hip fracture
6 Currie CJ, Poole CD, Gale EAM 2009 UK Diabetologia 6.671 629 Yes
The influence of glucose-lowering therapies on cancer risk in type 2
diabetes
7 Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C 1995 USA, UK Lancet 45.217 612 No
Risk of idiopathic cardiovascular death and nonfatal venous
thromboembolism in women using oral contraceptives with differing
progestagen components
8 Dial S, Delaney JAC, Barkun AN, Suissa S 2005 Canada Journal of the American
Medical Association
35.289 582 Yes
Use of gastric acid-suppressive agents and the risk of
community-acquired Clostridium difficile-associated disease
9 Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P,
Vallance P
2004 UK New England Journal of
Medicine
55.873 546 Yes
Risk of myocardial infarction and stroke after acute infection or
vaccination
10 Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB,
Gelfand JM
2006 USA Journal of the American
Academy of Dermatology
4.449 528 No
Prevalence of cardiovascular risk factors in patients with psoriasis
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What is also particularly interesting is the fact that
some of the scholars (and their institutions) in this list
are afﬁliated, to a certain extent, to these databases,
having served or currently acting as their founders,
directors, lead scientists or members of their scientiﬁc
committee.45 46 For example, lead scientists from the
Boston Collaborative Drug Surveillance Program in
Boston University were among the ﬁrst who developed
the technical and scientiﬁc capacity of these databases
in pharmacoepidemiological research.47 48
Research topics
We conducted a keyword analysis to identify important
topics of published research. For this, we ﬁrst extracted
from the bibliographic data set 5813 unique keywords as
indexed by Scopus30 to base our analysis on more com-
plete indexing information compared to authors’ key-
words. We retrieved the top 30 keywords for two speciﬁc
categories: medical conditions and medications/substances
(tables 11 and 12). Next, we created a (full counting of)
term co-occurrence density map in VOSviewer (ﬁgure 4)
by building a text corpus out of the title and abstract
ﬁelds in the bibliographic data set (minimum number
of a term occurrence=10). In this way, we were able to
identify topics that not only appear more frequently in
the literature, but that were also strongly related to each
other, forming clusters of topics. Blue indicates a low
density of terms and red indicates the highest density of
terms. In many cases, the density map represents the fre-
quency of indexed keywords in tables 11 and 12. Clearly,
smoking, diabetes, cardiovascular diseases, mental ill-
nesses, psoriasis, obesity, pregnancy and cancer as well as
medication and substances that can treat these medical
conditions, such as aspirin, insulin, antidepressants and
non-steroid anti-inﬂammatory agents (NSAIDs), have
been of great interest for scholars using EHRs in
primary care.
DISCUSSION
This study identiﬁed the leading institutions, countries,
authors, journals and topics as well as their networks of
published research that have used primary care data-
bases in the UK to extract and analyse data from EHRs.
There is a growing production of such papers which
indicates the interest of a global and highly collaborative
scientiﬁc community in this ﬁeld and also the knowl-
edge and insights that can be gained for healthcare
improvement. Publication output increased from 7
papers in 1995 to 171 by October 2015 (18.65% CAGR
for 1995–2014). It may be worth noting that by perform-
ing a similar, limited to the UK, search in Scopus for the
same period and with the keyword ‘primary care’ we
found a 10.83% CAGR, which shows the increase in
research conducted from these databases outstrips the
ﬁeld more generally. The vast majority of publications
(96.5%) were journal articles. While this research ﬁeld
Figure 2 Journal cocitation analysis.
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can be located, generally, in medicine, biochemical and
pharmaceutical developments seem to be equally
important, aimed at addressing widespread medical con-
ditions, such as diabetes, cardiovascular diseases, mental
illnesses, smoking, obesity and cancer.
The UK has been well placed in this scientiﬁc ﬁeld.
This is partly due to the fact that there is now more than
30 years of data available in GP information systems.49
The investment in developing primary care databases
from EHRs for research purposes has placed the
country at the centre of a network of collaborations
across the globe, bringing together international expert-
ise for the analysis of ever-expanding and increasingly
interlinked clinical data sets from primary, secondary
and tertiary care. Access to these data sets has also
allowed researchers and institutions from other coun-
tries to develop their own programmes of research to
answer important clinical questions. Six of the most pro-
ductive institutions are located in the UK, and 63.56%
of publications were authored by scholars afﬁliated with
this country, followed by the USA. Interestingly, the top
institutions were not exclusively universities. Among
them, we can ﬁnd a research unit in Spain (CEIFE) and
the executive agency in UK that funds and runs the
CPRD database (MHRA), while one of the most product-
ive scholars is afﬁliated with a pharmaceutical company.
This signiﬁes the great interest of various actors, from aca-
demic, governmental and private sectors, in research with
primary care databases.
The geographical trend can also be observed from the
location of journals with the most published papers. Six
of the top 10 journals are published in the UK, followed
by the USA. The journals with the most papers pub-
lished included Pharmacoepidemiology and Drug Safety,
BMJ, British Journal of General Practice and British Journal of
Clinical Pharmacology, which signiﬁes the great interest of
scholars in using data from EHRs for pharmaceutical
research. This is partially because one of the oldest sets
of routine information collected by GP practices in the
UK and made available by these databases is drug histor-
ies.47 Regarding restrictions on access to research
outputs, only four journals in this list are fully open
a-
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may limit access to knowledge to researchers and
members of the public that cannot afford subscription
costs. Interestingly, it is the more established journals in
medicine, such as JAMA, Lancet and NEJM, that have
published some of the most cited papers in this biblio-
metric data set and enjoy a high level of cocitation
activity.
Keyword analyses show that smoking, diabetes, cardio-
vascular diseases, mental illnesses, psoriasis, obesity,
pregnancy and cancer constitute the main topics of
research activity using EHRs in primary care. Often, this
research concentrates on developing algorithms to iden-
tify risk of occurrence of a particular disease. Researchers
are also interested in investigating medications that can
treat these medical conditions, such as aspirin, other
NSAIDs, insulin and antidepressants.
For the vast majority of publications, authorship varied
between three and six authors, indicating widely collab-
orative, international, efforts to promote research in this
ﬁeld. Coauthorship network analyses showed that the
lead scientists, directors and founders of these databases
were found, to various degrees, at the centre of clusters
in this scientiﬁc community, highlighting their invalu-
able contribution to knowledge production. As Azoulay
et al50 have demonstrated in their study about eminent
researchers and the vitality of a ﬁeld, the development
of coauthorship networks and clusters of collaborators
in newly established scientiﬁc domains might be useful
to boost research productivity. On the basis of each data-
base’s data access requirements, their established
researchers appear to have a fundamental role in facili-
tating and promoting international collaborations for
Figure 3 Clustered coauthor network.
10 Vezyridis P, Timmons S. BMJ Open 2016;6:e012785. doi:10.1136/bmjopen-2016-012785
Open Access
group.bmj.com on December 5, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
more researchers, institutions and countries.
Importantly, they have a clear and in-depth understand-
ing of the kind of research activities these databases can
support in terms of data quality, structure and EHR
coding practices. As these databases are expected to
open up in the future to more stakeholders from various
disciplines around health and as universities prepare to
incorporate training in data science skills (eg, statistics,
biomedical informatics, biology and medicine)51 into
their clinical curricula, so as to nurture the next gener-
ation of clinical investigators,52 these established
researchers could promote quality, reliable and ethically
appropriate scientiﬁc research53 from complicated and
highly contextual data sets.
Our study has the typical limitations of a scientometric
study. We analysed articles published in a period of
20 years in order to explore the historical breadth and
growth of research from electronic primary care records.
However, this analysis is limited on structured data
retrieved from one bibliometric database of peer-
reviewed literature. Therefore, only articles published in
journals in its index were analysed. Also, some of the
latest articles and related citations might not have been
retrieved at the time of the search, which might explain
the decrease in the number of publications and citations
particularly from 2010 onwards. It was beyond the scope
of this quantitative study to assess the scientiﬁc quality
and the socioeconomic impact of the large number of
publications analysed here. These studies have deployed
a range of study designs across many subﬁelds of
primary care research and with various research ﬁnd-
ings. Our main objective was restricted to assessing one
aspect of academic impact and research quality, that is,
patterns and trends in research outputs.54 Future
Table 11 Top keywords: medical conditions
Rank Keyword Occurrences Rank Keyword Occurrences
1 Smoking 328 16 Cardiovascular diseases 96
2 Diabetes mellitus 223 17 Myocardial infarction 94
3 Hypertension 223 18 Chronic obstructive lung disease 90
4 Non-insulin dependent diabetes mellitus 179 19 Heart failure 86
5 Depression 167 20 Cerebrovascular accident 85
6 Stroke 165 21 Rheumatoid arthritis 83
7 Asthma 158 22 Epilepsy 81
8 Diabetes mellitus, type 2 155 23 Breast cancer 78
9 Cancer risk 150 24 Fracture 75
10 Cardiovascular risk 147 25 Psoriasis 75
11 Cardiovascular disease 133 26 Gastrointestinal haemorrhage 69
12 Obesity 129 27 Hip fracture 68
13 Heart infarction 126 28 Osteoporosis 68
14 Pregnancy 125 29 Colorectal cancer 65
15 Ischaemic heart disease 104 30 Fractures, bone 65
Table 12 Top keywords: medications/substances
Rank Keyword Occurrences Rank Keyword Occurrences
1 Non-steroid anti-inflammatory agent 182 16 Proton pump inhibitor 75
2 Acetylsalicylic acid 154 17 Warfarin 71
3 Metformin 150 18 Antidiabetic agent 69
4 Corticosteroid 143 19 Anticonvulsive agent 68
5 Hydroxymethylglutaryl coenzyme a
reductase inhibitor
138 20 Serotonin uptake inhibitor 65
6 Insulin 133 21 Calcium channel blocking agent 64
7 Antidepressant agent 124 22 Antibacterial agents 62
8 β adrenergic receptor blocking agent 108 23 Hydroxymethylglutaryl-coA reductase
inhibitors
62
9 Hypoglycemic agents 91 24 Oral antidiabetic agent 61
10 Anti-inflammatory agents,
non-steroidal
90 25 Paracetamol 56
11 Dipeptidyl carboxypeptidase inhibitor 88 26 Diuretic agent 53
12 Antihypertensive agent 82 27 Ibuprofen 52
13 Neuroleptic agent 80 28 Simvastatin 52
14 Antibiotic agent 77 29 Tricyclic antidepressant agent 52
15 Hemoglobin A1c 75 30 Diclofenac 50
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research could focus on the wider academic and socio-
economic impact of these studies by examining the rela-
tionship between publications, citation patterns and
collaborations with the development of new scientiﬁc
methods in the ﬁeld or of new medical products and
healthcare services.
In conclusion, output of primary care research from
EHRs has consistently increased since their develop-
ment. The development of these databases in the UK
has placed the country and afﬁliated academic institu-
tions at the centre of an expanding global scientiﬁc
community, facilitating international collaborations and
bringing together international expertise in medicine,
biochemical and pharmaceutical research.
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